Demeetra Completes Acquisition of Hera BioLabs, Securing Expanded Rights to Hyperactive Super piggyBac® Transposase
Demeetra AgBio, a genome engineering company enabling research and biomanufacturing through advanced gene-editing technologies and engineered CHO host cells, announced the completion and full integration of its acquisition of Hera BioLabs. The transaction, completed June 1, resulted in Demeetra now holding expanded rights to the hyperactive Super piggyBac® transposase platform and technologies, establishing Demeetra as the definitive commercial source for licensing and access across broad fields of use.
